Not independent
Tenure on this board
6.9 yrs
2 nominees · 2 ballot items.
Vote to elect two Class I directors (Jason Coloma, Ph.D. and Neil Kumar, Ph.D.) and to ratify Ernst & Young LLP as the company’s independent registered public accounting firm for 2026.
Elect Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as Class I directors to serve three-year terms expiring at the 2029 annual meeting.
Ratify the appointment of Ernst & Young LLP as Maze Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 8.25% | 4,567,274 | $136M |
| 2 | TRV GP IV, LLC | 8.08% | 4,473,958 | $134M |
| 3 | ARCH Venture Management, LLC | 7.44% | 4,120,053 | $123M |
| 4 | Deep Track Capital, LP | 6.28% | 3,477,562 | $104M |
| 5 | JANUS HENDERSON GROUP PLC | 5.17% | 2,858,876 | $85M |
| 6 | Paradigm Biocapital Advisors LP | 4.96% | 2,744,399 | $82M |
| 7 | a16z Capital Management, L.L.C. | 3.08% | 1,702,225 | $51M |
| 8 | Venrock Adviser, LLC | 2.89% | 1,602,034 | $48M |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 2.59% | 1,435,656 | $43M |
| 10 | Alphabet Inc. | 2.51% | 1,388,583 | $41M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.